Introduction {#s001}
============

Kidney transplantation is an effective therapy for most of the end-stage renal disease patients. As the extending criteria of deceased kidney donors, the rates of delayed graft function (DGF) or primary graft nonfunction (PGN) are increasing. The occurrence of DGF and PGN can be caused by many aspects, such as ischemia/reperfusion injury (IRI), immunological rejection, primary diseases of the recipients, and the quality of the graft. However, there is no effective treatment for DGF and PGN after kidney transplantation.

IRI is one of the most important but unavoidable risk factors for causing the impairment of graft function. Renal IRI triggers the generation of reactivate oxygen species, causing oxidative injury, acute inflammation and eventually necrosis, and apoptosis of renal tubular epithelial cells (Gu *et al.*, [@B11]; Situmorang and Sheerin, [@B33]). These responses can evoke the anti-inflammatory and repair processes to initiate the recovery of the graft function (Sanchez-Nino *et al.*, [@B30]; Pressly and Park, [@B28]). On the contrary, many factors released during the IRI, such as transforming growth factor-β, matrix metalloproteinases (MMPs), and altered extracellular matrix (ECM) components, can induce epithelial--mesenchymal transition, ECM remodeling, and interstitial fibrosis (Jain *et al.*, [@B17]; Danobeitia *et al.*, [@B7]; Kim *et al.*, [@B21]; Liu *et al.*, [@B23]), which hinder the recovery of complete function. Therefore, IRI is a complex and multistep pathological process that the mechanism has not been fully clarified yet. Identifying novel targets of renal IRI is crucial for exploring the diagnosis and treatment of DGF or PGN after kidney transplantation. In the present study, we screened for differentially expressed genes in renal IRI based on an experimental IRI model.

Materials and Methods {#s002}
=====================

Animal studies {#s003}
--------------

All the studies related to animals were approved by the Beijing Friendship Hospital Animal Care and Use Committee (approval no.: 2018-P2-167-01). The renal IRI experiments were performed as previously described (Hesketh *et al.*, [@B14]). In brief, 8-week-old male C57/BL6 mice were anesthetized through intraperitoneal injection of pentobarbital sodium (0.05 mg/g body weight). The mice were randomly divided into injury and sham-treated groups. For IRI treatment, the mice were subjected to 45 min of ischemia by bilaterally clamping the renal artery. After 24 h of reperfusion, the mice were euthanized and the kidney samples were immediately frozen at −80°C or fixed in 4% paraformaldehyde for further analysis.

Microarray assay {#s004}
----------------

Total RNA from the kidney samples was extracted using TRIzol reagent (Thermo Fisher Scientific, Schuylerville, NY). The differentially expressed genes were detected using an Affymetrix Mouse Genome 430 2.0 microarray (Thermo Fisher Scientific) from three mice of renal IRI and three sham-treated mice. The experimental procedures for microarray were performed at the Shanghai Biotechnology Corporation (Shanghai, China). The differential expression genes fulfill at least twofold change and *p* \< 0.05 were considered for further analysis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were performed.

### RNA extraction and real-time qPCR analysis {#s005}

Total RNA from kidney samples was extracted with the miRNeasy Mini Kit (Qiagen, Hilden, Germany). For quantitative detection of mRNA or lncRNA, the complementary DNAs (cDNAs) were synthesized with a cDNA Synthesis Kit (Takara, Dalian, China). The real-time qPCR was performed by using the following specific primers: *MMP-10*, 5′-TCCAGGAATTGAGCCACAAG-3′ and 5′-GCATTGGGGTCAAACTCGAAC-3′; *SPRR1A*, 5′-GAGAACCTGCTCTTCTCTGAGT-3′ and 5′-CAAGGTTCCTGGGGTGGTG-3′; *SPRR2F*, 5′-GGAGAACCTGATCCTGAGGC-3′ and 5′-CCCTGTCCTGAAGACTGCTG-3′; *Malat1*, 5′-TGCAGTGTGCCAATGTTTCG-3′and 5′-GGCCAGCTGCAAACATTCAA-3′. *GAPDH* was used as an internal control, and the primers are: 5′-GGCAAATTCAACGGCACAGT-3′ and 5′-AGATGGTGATGGGCTTCCC-3′. For the detection of mature form of *miRNA-139-5p*, the specific primer containing a stem-loop structure (5′-CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGACTGGAGA-3′) was used for reverse transcription, and the specific primers were used for amplification: 5′-ACACTCCAGCTGGGTCTACAGTGCACGTGTC-3′ and 5′-TGGTGTCGTGGAGTCG-3′. The ribosomal *U6* was used as an internal control for normalization: 5′-CTCGCTTCGGCAGCACA-3′ and 5′-AACGCTTCACGAATTTGCGT-3′.

Immunochemistry staining {#s006}
------------------------

Kidney tissues fixed in 4% paraformaldehyde were dehydrated and embedded in the paraffin. The samples were cut into 4 μm thick sections. The sections were then dewaxed and rehydrated. The antigen was repaired by a heating process, and the endogenous peroxidases were blocked with 3% H~2~O~2~ for 20 min at room temperature. After washed with phosphate-buffered saline (PBS) for three times, the sections were incubated with rabbit anti-MMP-10 primary antibody (BBI; Sangon Biotech, Shanghai, China) at 4°C overnight. After that, the sections were washed three times with PBS and incubated in an HRP/Fab polymer-conjugated secondary antibody (ZSGB-BIO, Beijing, China) for 30 min at room temperature. The sections were then washed for five times with PBS and were developed using a diaminobenzidine reagent. The nuclei were counter stained with hematoxylin and visualized with a microscopy.

Protein extraction and western blotting {#s007}
---------------------------------------

Total protein from tissue samples were extracted with RIPA lysis buffer containing protease and phosphatase inhibitors. The lysates were centrifuged with 12,000 round per minute at 4°C for 10 min. The supernatants were collected and quantified using bicinchoninic acid (BCA) assay (Thermo Fisher Scientific). The protein samples were normalized and diluted at a final concentration of 5 μg/μL. For electrophoretic separation, a total of 50 μg proteins from each sample were loaded onto a sodium dodecyl sulphate (SDS) polyacrylamide gel. After the electrophoresis, the proteins on the SDS polyacrylamide gel were blotted onto a nitrocellulose membrane and then blocked with 5% nonfat milk at room temperature for 1 h. After that, the membrane was incubated with specific antibodies: rabbit anti-MMP-10 (BBI; Sangon Biotech) and mouse anti-β-actin (Santa Cruz, Dallas, TX). The membrane was washed with TBS-T and incubated with HRP-conjugated goat anti-rabbit or mouse secondary antibodies (ZSGB-BIO) for 1 h at room temperature. After washing with TBS-T for four times, the specific bands were developed using Super Signal West Femto Maximum Sensitivity Substrate (Pierce, Rockford, IL) and scanned using Quantity One software V 4.6.2 (Bio-Rad, Hercules, CA). The expression of *β-actin* was used as an internal control.

Statistical analysis {#s008}
--------------------

All the statistical calculations were performed with SPSS 19.0 software (SPSS, Inc., Chicago, IL). A two-tailed Student\'s *t*-test was used for analyzing the differences between two groups. *p* \< 0.05 was considered as statistically significant.

Results {#s009}
=======

Screening for differential expression genes in renal IRI {#s010}
--------------------------------------------------------

Previously, we found 2218 differentially expressed genes, including 1103 upregulated genes and 1115 downregulated genes by using microarray assay ([Fig. 1a](#f1){ref-type="fig"}; Hu *et al.*, [@B16]). In the present study, GO and KEGG enrichment analyses were performed, and the top 30 enrichments were listed, respectively ([Fig. 1b, c](#f1){ref-type="fig"}, complete data see [Supplementary Tables S1](#SD1){ref-type="supplementary-material"} and [S2](#SD2){ref-type="supplementary-material"}). We found that many essential pathways were associated with renal IRI, such as tumor necrosis factor signaling pathway, MAPK signaling pathway, Hif-1 signaling pathway, ECM-receptor interaction, focal adhesion, keratinocyte development, Toll-like receptor signaling, IκB/NF-κB signaling pathway, positive regulation of pri-miRNA transcription, and metanephric nephron tubule development.

![Screening for differentially expressed genes in renal IRI. **(a)** Volcano plot diagram of differentially expressed genes (≥2-fold, *p* \< 0.05) from IRI-treated and sham-treated mice (*n* = 3 per group). **(b, c)** Top 30 pathways from Gene Ontology **(b)** and Kyoto Encyclopedia of Genes and Genomes **(c)** enrichment analysis are shown. IRI, ischemia/reperfusion injury. The image can be magnified online for greater readability. Color images are available online.](fig-1){#f1}

*SPRR2F* and *SPRR1A* is upregulated in renal IRI {#s011}
-------------------------------------------------

Keratinocytes are known to participate in IRI, and the keratinocyte-derived chemokine is a known biomarker for indicating early renal injury before the increase of serum creatinine (Molls *et al.*, [@B27]). Data from GO enrichment analysis ([Fig. 1b](#f1){ref-type="fig"}) also supported that genes-related keratinocytes might be potential biomarkers of IRI. By analyzing these differentially expressed genes, we found that the expression of *SPRR2F* and *SPRR1A*, annotated as "keratinocytes differentiation," was significantly upregulated in the kidney tissues of IRI mice. The results from real-time qPCR consistently verified that the expression of *SPRR2F* in kidneys of IRI mice was 479.3-fold higher than the sham-operated mice ([Fig. 2a](#f2){ref-type="fig"}). Likewise, the expression of *SPRR1A* increased up to 4.98-fold of the sham-treated group ([Fig. 2b](#f2){ref-type="fig"}). Our data indicated that the *SPRR2F* and *SPRR1A* might be involved in IRI.

![*SPRR2F* and *SPRR1A* are upregulated in IRI. **(a, b)** The expression of *SPRR2F* **(a)** and *SPRR1A* **(b)** was determined using a real-time qPCR assay. *GAPDH* was used as an internal control for normalizing. Data are expressed as mean ± standard deviation, and \*\**p* \< 0.01 versus the sham-operated group (*n* = 4 per group).](fig-2){#f2}

The expression of *MMP-10* is activated in renal IRI {#s012}
----------------------------------------------------

ECM degradation and renal remodeling are important pathological changes of IRI hindering the recovery of kidney. During the acute phase, breakdown of normal structures of ECM aggravates kidney injury, whereas the interstitial fibrosis impairs kidney function in the chronic phase. From the data of the differentially expressed genes of IRI, we found that *MMP-10*, an enzyme mediating the degradation of ECM, was significantly upregulated by IRI treatment. By using real-time qPCR, we observed that *MMP-10* was highly expressed in all the mice undergone IRI operation ([Fig. 3a](#f3){ref-type="fig"}). In contrast, *MMP-10* is undetectable in most of the mice of the sham-operated group. The products from real-time qPCR were visualized through an ultraviolet imager ([Fig. 3b](#f3){ref-type="fig"}).

![*MMP-10* is induced by renal IRI. **(a, b)** The expression of *MMP-10* was measured using a real-time qPCR assay **(a)**. *GAPDH* was used as an internal control. Data are expressed as mean ± standard deviation and \*\**p* \< 0.01 versus the sham-operated group (*n* = 4 per group). The qPCR of products were separated by agarose electrophoresis and observed through an ultraviolet imager **(b)**. **(c, d)** The protein levels of renal *MMP-10* was detected using western blotting **(c)**. The expression intensity for each band was scanned and normalized to the β-actin intensity in each lane **(d)**. **(e)** Immunohistochemistry staining was performed to localize the MMP-10 in kidney tissues. Scale bars: 50 μm. MMP, matrix metalloproteinases.](fig-3){#f3}

We then analyzed the expression of *MMP-10* at protein levels, using western blotting. We found that *MMP-10* was indeed upregulated in kidneys of IRI-treated mice ([Fig. 3c, d](#f3){ref-type="fig"}). Interestingly, *MMP-10* was presented in kidney tissues of sham-operated mice, which is not paralleled with the results of its mRNA level. Consistently, data from immunohistochemistry staining indicated that *MMP-10* was strongly stained in the injury area of the kidney, but weakly stained in kidneys of sham-operated mice ([Fig. 3e](#f3){ref-type="fig"}). Our data suggested that *MMP-10* might be a potential molecular candidate participating in renal IRI.

The expression of *Malat1* and *miR-139-5p* in renal IRI {#s013}
--------------------------------------------------------

Noncoding RNAs, including miRNAs, lncRNAs, and circular RNAs (circRNAs), play important roles in many biological processes. Our data of microarray screened that the lncRNA *Malat1* was upregulated in IRI. The real-time qPCR verified that *Malat1* in kidneys of IRI mice was increased to 3.79-fold compared with the sham-operated mice ([Fig. 4a](#f4){ref-type="fig"}). In addition, we detected the expression of *miR-139-5p*, which is not included in the microarray data but closely associated with cell proliferation. IRI treatment repressed the renal *miR-139-5p* expression to 40.4% of the sham-operated mice ([Fig. 4b](#f4){ref-type="fig"}). These data demonstrated that both noncoding RNAs *Malat1* and *miR-139-5p* were involved in IRI.

![The expression of lncRNA *Malat1* and *miR-139-5p* in kidneys of IRI. **(a)** The expression of lncRNA *Malat1* in kidneys was detected using real-time qPCR assay. *GAPDH* was used as an internal control. **(b)** The relative expression of *miR-139-5p* was detected using a "stem-loop" qPCR method. *U6* was used as an internal control. Data are expressed as mean ± standard deviation and normalized using a 2^−ΔΔCt^ assay. \**p* \< 0.05 and \*\**p* \< 0.01 versus the sham-operated mice (*n* = 4 per group). lncRNA, long noncoding RNA.](fig-4){#f4}

Discussion {#s014}
==========

Renal IRI is a main risk factor for the occurrence of DGF and PGN in kidney transplantation. IRI is a multistep pathological process and is currently not fully clarified. Therefore, it lacks an ideal biomarker for the diagnosis and treatment. Recipients undergo IRI of the graft frequently requires a redialysis, causing heavy burden both physically and mentally. Therefore, identification of novel molecular biomarkers is important for the diagnosis and treatment of DGF and PGN. Previously, we screened differentially expressed genes in experimental IRI models through a microarray assay. In the present study, we used these data to perform enrichment analysis and identified that *SPRR2F*, *SPRR1A*, *MMP-10*, and *Malat1*were significantly altered in our experimental models, indicating that these genes may be involved in renal IRI.

*SPRR2F* and *SPRR1A* belong to the small proline-rich protein family, which are both important markers of keratinocyte terminal differentiation (Sark *et al.*, [@B31]; Chen *et al.*, [@B5]). *SPRR2F* is highly expressed in uterus and ovary (Song *et al.*, [@B35]; Cabral *et al.*, [@B2]) and briefly expressed during nephrogenesis (Schwab *et al.*, [@B32]). We observed that *SPRR2F* was seldom expressed in normal kidney tissues, but could be strongly induced by IRI treatment. The function of *SPRR2F* remains far from understanding. In contrast, *SPRR1A*, another member of *SPRR* family, is well profiled and is known to be associated with many diseases, such as breast cancer and diffuse large B cell lymphoma (Zhang *et al.*, [@B42]; Chen *et al.*, [@B4]). *SPRR1A* is a gene related with tissue regeneration (Gaudet *et al.*, [@B9]; Gey *et al.*, [@B10]; Danaher *et al.*, [@B6]) and can be controlled by *ATF3* (Danaher *et al.*, [@B6]). In the present study, we found an increased expression of *SPRR1A* in kidneys of IRI-treated mice. Therefore, we speculate that *SPRR2F* and *SPRR1A* are biomarkers of kidney repair and regeneration after IRI, which may reflect the recovery of the kidney function. However, the detailed role of *SPRR2F* and *SPRR1A* in renal IRI remains to be investigated.

Most of the *MMPs* are secreted enzymes mediating ECM degradation. *MMP-10* (also known as *stromelysin 2*, *SL-2*) belongs to the stromelysins subgroup of *MMPs*, catalyzing substrates include collagen IV, laminin, fibronectin, and elastin. *MMP-10* was reported to be associated with atherosclerosis (Purroy *et al.*, [@B29]), intracerebral hemorrhage (Howe *et al.*, [@B15]), pulmonary hypertension (Avouac *et al.*, [@B1]), and cancers (Miyata *et al.*, [@B26]; Du *et al.*, [@B8]; Kadeh *et al.*, [@B20]; Juchniewicz *et al.*, [@B19]). Recently, Guvercin *et al.* reported that the increase of serum *MMP-10* is related to acute kidney injury in nondiabetic geriatric patients (Guvercin *et al.*, [@B13]). Our data demonstrated that the expression of *MMP-10* in normal kidney tissues is very weak, but could be strongly activated by IRI treatment, supporting that *MMP-10* is a potential candidate involved in renal IRI. Interestingly, we observed that the expression of *MMP-10* at mRNA level was not paralleled with its protein level in normal kidney tissues. Because mature form of MMP-10 enzyme can be secreted into the circulation, we postulate that the circulatory MMP-10 in the plasma may be recruited to the kidney, causing the present of MMP-10 protein in the kidney tissues. Due to the stromelysin activity, the upregulation of *MMP-10* in tissues results in the degradation and remodeling of the ECM (Avouac *et al.*, [@B1]), further causing intestinal fibrosis and thus hindering the recovery of kidney function (Sokai *et al.*, [@B34]). Our data indeed showed a significant accumulation of MMP-10 in the injured area of the kidney, indicating that tissue MMP-10 may be a potential biomarker to reflect the severity of tissue injury. We speculate that MMP-10 may be a potential therapeutic target for acute kidney injury.

From the data of the differentially expressed genes, we found that lncRNA *Malat1* was upregulated in kidneys of IRI-treated mice, which has been reported from other groups (Kölling *et al.*, [@B22]; Tian *et al.*, [@B37]). However, these reports remain controversy. Tian *et al.* reported that the increase of *Malat1* inhibits hypoxia-induced inflammation (Tian *et al.*, [@B37]), whereas Kölling, *et al.* speculated *Malat1* as dispensable (Kölling *et al.*, [@B22]). Our data support that Malat1 participates in IRI, but its role remains to be clarified. In addition to the high throughput data, we identified that *miR-139-5p* was decreased in renal IRI. *miR-139-5p* was reported to inhibit tumorigenesis and reverses drug resistance in many cancers (Wang *et al.*, [@B38]; Jiang *et al.*, [@B18]; Zhang *et al.*, [@B43]). Targets of *miR-139-5p*, such as c-Jun (Jiang *et al.*, [@B18]; Su *et al.*, [@B36]), PI3K/Akt (Maoa *et al.*, [@B25]; Catanzaro *et al.*, [@B3]), IGF-1/IGF-1R (Xu *et al.*, [@B41]), VEGF, and Wnt/β-catenin (Long *et al.*, [@B24]; Xie and Shen, [@B40]), are potent stimulators of cell proliferation, some of which are important pathways promoting injury repair (Zhou *et al.*, [@B44]; Guise and Chade, [@B12]; Xie *et al.*, [@B39]). Therefore, we postulate that the downregulation of *miR-139-5p* may reflect an activation of cell proliferation, promoting the repair and regeneration of injured kidney.

Taken together, our data indicated that the expression of *SPRR2F*, *SPRR1A*, *MMP-10*, *Malat1*, and *miR-139-5p* in kidney was altered by IRI, which may serve as potential biomarkers for renal IRI. These findings may also provide evidences for exploring novel targets for the prevention and treatment of DGF and PGN after kidney transplantation.
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